Mentara Therapeutics
Breaking New Ground in Levodopa-Induced Dyskinesia (LID) in Parkinson’s Disease
Biotechnology Research·0 Followers
Overview
Mentara Therapeutics is a privately held, clinical stage biotech focused initially on the development of a new drug for patients with levodopa induced dyskinesia (LID) in Parkinson's disease. The Company’s lead product, MTA-304, is a potentially best-in-class, highly potent, oral, once-a-day 2nd generation PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. Mentara has completed three successful Phase 1 studies and plans to initiate a Phase 2 study in Q1 2...See more
Website
https://www.mentaratherapeutics.com/Industry
Biotechnology Research
Company size
3 employees
Headquarters
San Diego, CA
Founded
2026
Upgrade to view team
View current team members and their roles
Access founders information
Request warm introductions
Funding Rounds (1)
Funding Round
Announced on 10/12/2026
Open Positions(0)
No open jobs posted for this organization yet.
Company Updates
No updates available yet.